Amedisys (AMED)
(Delayed Data from NSDQ)
$90.05 USD
-0.24 (-0.27%)
Updated Nov 15, 2024 03:59 PM ET
After-Market: $90.07 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
AMED 90.05 -0.24(-0.27%)
Will AMED be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMED
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
The Pennant Group, Inc. (PNTG) Q3 Earnings and Revenues Beat Estimates
Other News for AMED
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
Highbridge Capital Management LLC Acquires New Stake in Nutex Health Inc
Highbridge Capital Management's Strategic Acquisition of Precision BioSciences Shares
Highbridge Capital Management LLC Acquires New Stake in Melar Acquisition Corp I
Highbridge Capital Management's Strategic Acquisition of Velo3D Inc Shares